Malignant melanoma of the canine
BuBu(dog)Canine Malignant Melanoma – Inner Side of Third toe on Left Hind Limb
Detail

Pet Medical Care Division
Clinical Preliminary Trial Case
Canine MalignantMelanoma – Inner Side of Third toe on Left Hind Limb

 








Object Animal
Dog

BreedGolden Retriever

NameBuBu

GenderFemale

Age12 years old

Weight45-47 kg

Diagnosis: Malignant melanoma on inner side of third toe of left hind limb.

 

Case background:

In the beginning of May 2020, the owner discovered that BuBu had swelling on her third toe of left hind limb, which was diagnosed as malignant melanoma after staining  of fine needle aspiration. At the same time, BuBu suffered from indolent lymphoma and perianal sarcoma. After the vet’s evaluation, the owner decided to locally control the malignant melanoma first to maintain normal walking function and good quality of life for BuBu. Diagnosis and treatment of other indications would follow based on BuBu condition.



Gongwin Biopharm Co., Ltd. started Pet Drug Project in December 2018, and obtained the approval from the Bureau of Animal and Plant Health Inspection and Quarantine, COA, Executive Yuan (Prevention Inspection First No.1081415339) in November 2019 for the implementation of field trials on dogs; meanwhile, Taipei City Animal Protection Office visited Gongwin Biopharm to complete the inspection and verification on special labels for animal trial production of drug samples (Animal Protection Inspection No. 1086026496); in February 2020, the Bureau of Animal and Plant Health Inspection and Quarantine, COA, Executive Yuan, agreed to expand the field pre-test sites (Prevention Inspection First No 1091400445).




BuBu received seven Intratumoral injection treatments of "animal drug sample trial production of PTS", a total of 19 mL.


After the malignant melanoma was injected intratumorally with "animal drug sample trial production of PTS”, the tumor appeared to be filled with drug liquid; as the drug liquid was absorbed and metabolized, the malignant melanoma gradually shrank.; and after ten debridements, the malignant melanoma had no measurable volume on the 16th day. At the same time, the proliferation of granulation tissues and skin tissues were in good condition. BuBu was still able to maintain walking function and normal diet during the treatment.


BuBu underwrnt abdominal ultrasound, X-ray detection, and cardiac function examination on the 37th day. The results of above examinations showed that the melanoma had no signs of metastasis during the pre-trial treatment of "animal drug sample trial production of PTS”.



After seven PTS intratumoral injections and ten wound debridements, the wound completely healed on the 61st day, and BuBu could swim happily in the water. The Pet Medical Care Division is honored to have gained the trust of its owners, so that Gongwin Biopharm is able to provide more treatment options for pets suffering from tumors. The Pet Medical Care Division of Gongwin Biopharm will continue to make every effort to contribute to the treatment of dogs suffering from tumors.


Video



If your dog has any of the following indications, please contact Gongwin Biopharm Pet Medical Care Division.

  • Malignant peripheral nerve sheath tumor (MPNST)
  • Malignant melanoma
  • Lipoma
  • Bladder Cancer
  • Or superficial tumors that can receive intratumoral injection of PTS, as assessed by a veterinarian
Entrusted clinical preliminary trial unit
  1. Evergreen Animal Hospital
  2. Aurora Animal Hospital
  3. WellcareVet Animal Hospital
  4. TZUOO-ANN Animal Hospital

Contact
Pet Medical Care Division

*Project Manager:Cherry Chen  Ext. 313
 cherry.chen@gongwinbiopharm.com

*Project Manager:
Sarina Cheng  Ext. 306
sarina.cheng@gongwinbiopharm.com

*Specialist:Megan Feng Ext. 316
megan.feng@gongwinbiopharm.com